Phase II Trial of Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Jul 2018
Price : $35 *
At a glance
- Drugs Crizotinib (Primary)
- Indications Uveal melanoma
- Focus Therapeutic Use
- 29 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 10 May 2016 Planned number of patients changed from 30 to 10.
- 10 May 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2019.